The Indian embassy announced on Friday that Bahrain had become the latest country to approve Covaxin, the made-in-India vaccine against the coronavirus disease (Covid-19) after the country’s National Health Regulatory Authority (NHRA) granted permission for the jab’s emergency use. The approval is consistent with the Bahrain government’s guidelines, which state that travelers who have received a Covid-19 vaccine approved by the Bahrain government or the World Health Organization (WHO) will not be required to undergo quarantine on such arrival.
“As a result, passengers traveling from India to Bahrain with valid Covid vaccination certificates issued in India with a scannable QR code for vaccines authorized by WHO, or by the Kingdom of Bahrain, will be excluded from mandatory 10 days isolation as well as pre-arrival negative RTPCR certificate,” the embassy said on November 6, three days after the jab, established by Hyderabad-based Bharat Biotech, received an emergency use listing from the global health governing body.
Covaxin was conferred emergency use authorization (EUA) by the NHRA on November 11, according to a press release. As per the release, it will be used to vaccinate those aged 18 and up in Bahrain, the same age range for which the vaccine is being used in India.
Covaxin has recently been acknowledged by many countries, along with the United States, the United Kingdom, and Australia, among others. The WHO has now authorized the shot, and the number of countries that recognize it is expected to grow in the coming days.
In addition, the medical journal The Lancet has peer-reviewed and published data from Covaxin’s Phase-3 clinical trials, corroborating the vaccine manufacturer’s June statement that the jab has a 77.8 percent efficacy against mild symptomatic cases and a 93% efficacy against severe symptomatic cases.